摘要
目的研究莫西沙星治疗耐多药肺结核的临床疗效。方法选取我院收治的80例耐多药肺结核患者作为研究对象,所有患者随机分为两组:A组40例,采用莫西沙星口服,加利福喷丁、对氨基水杨酸、异烟肼口服和阿米卡星静脉给药;B组40例,左氧氟沙星及利福喷丁、对氨基水杨酸、异烟肼口服和阿米卡星静脉给药。经过4个月的治疗后,比较两组患者的血常规、血生化指标变化,临床疗效和不良反应发生情况。结果 4个月后,A组38例患者完成研究;B组39例患者完成研究。A组35例(92.11%)患者细菌阴性,35例(92.11%)患者空洞闭合,36例(94.74%)患者病灶吸收;B组26例(66.67%)患者细菌阴性,25例(64.10%)患者空洞闭合,27例(69.23%)患者病灶吸收,差异具有统计学意义(P<0.05)。莫西组有效率为94.74%(36/38),左氧组有效率为79.49%(31/39),差异具有统计学意义(P<0.05)。莫西组不良反应发生率为10.53%(4/38),左氧组为12.82%(5/39),差异无统计学意义(P>0.05)。结论莫西沙星治疗耐多药肺结核的疗效好,安全性较为可靠。
Objective To study the effect of moxifloxacin in the treatment of multi-drug resistant tuberculosis. Methods 80 patients with MDR-TB were chosen as study objects,and all patients were randomly divided into two groups： 40 cases in the group A（ moxifloxacin ＋ rifapentine ＋ isoniazid ＋ aminosalicylate ＋ amikacin） and 40 cases in the group B（ levofloxacin ＋ rifapentine ＋ isoniazid ＋ aminosalicylate ＋ amikacin）. After 4 months,their blood routine,blood biochemistry,effective rate and side reactions were compared between the two groups. Results38 patients in the group A and 39 patients in the group B completed the study. In the group A,the negative rate of bacteria was 92. 11%（ 35 /38）,the close rate was 92. 11%（ 35 /38）,and the absorption rate was 94. 74%（ 36 /38）. In the group B,the negative rate of bacteria was 66. 67%（ 26 /39）,the close rate was 64. 10%（ 25 /39）,and the absorption rate was 69. 23%（ 27 /39）（ P〈 0. 05）. The effective rate of the group A was 94. 74%（ 36 /38）,and69. 23%（ 27 /39） in the group B（ P〈 0. 05）. The incidence of side reactions was 10. 53%（ 4 /38）,and 12. 82%（ 5 /39） in the group B（ P〉 0. 05）. Conclusion Moxifloxacin has promising effect in the treatment of multi-drug resistant tuberculosis,with reliable safety.
出处
《临床肺科杂志》
2016年第1期25-29,共5页
Journal of Clinical Pulmonary Medicine
